Drug intelligence / Profile preview

Spectrobab

Development stage: Preclinical
Lead developer: Chengdu Kangnuoxing Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Injection

Overview

Spectrobab is a monoclonal antibody targeting the interleukin-4 receptor subunit alpha (IL-4Rα). It is currently under investigation for its safety and efficacy in the treatment of adult secretory otitis media. The drug is being developed by Chengdu Kangnuoxing Biopharma,Inc.

Other names: IL-4Rα Monoclonal Antibody司普奇拜单抗

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on Spectrobab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spectrobab.

Explore the full profile